



THE UNITED INDUSTRY VOICE FOR AUSTRALIAN GENOMICS

Message from the CEO

12 January 2026

Dear members and friends,

Welcome to 2026. A year of momentum, alignment and action.

Happy New Year to our InGeNA community. As we begin 2026, there is a strong sense of energy and optimism across Australia's genomics and precision medicine ecosystem. This year is shaping up to be an inflection point, with aligned leadership, shared ambition and a growing focus on translating innovation into equitable access for Australians.

A strong start to the year

The year has already begun with important discussions involving government, patient advocacy organisation leaders and industry partners. Across these conversations, a clear and consistent theme has emerged: how we scale access to genomics in a way that is sustainable, equitable and nationally coordinated.

A key shared priority is *Comprehensive Genomic Profiling* at diagnosis for all cancer patients by 2030. This ambition is widely supported across clinical, patient and industry stakeholders. The focus now is on how we make this happen in practice. That includes understanding the current landscape, identifying gaps, and investing wisely in the digital, data and enabling infrastructure required. Horizon scanning, clarity on readiness, and coordination across jurisdictions will be critical. What is encouraging is the depth of alignment and passion across the ecosystem. In 2026, our opportunity is to connect these efforts and accelerate progress.

Activating our strategy and Board leadership

InGeNA enters 2026 with a vibrant, talented and highly engaged Board, and a clear focus on activating our strategy for the coming year. InGeNA's Board now has nine member which include 5 Member elected directors, 3 Independent directors and our Independent Chair - Carl Stubbings. We warmly welcome two new independent

Board Directors, Sandra Owens and Monica Ferrie, whose experience and perspectives strengthen our leadership across industry and consumer engagement.

Carl has recently returned from the JPMorgan Healthcare Conference in the US, where he represented InGeNA alongside his broader industry engagements. We look forward to hearing his direct insights on global investment trends, and the US and international markets, next week at our first member meeting for the year. These meetings are a vital way for our community to stay connected, informed and strategically aligned.

Genomics Australia officially launched its website December 16th and includes a sign-up for new networks. The *dedicated Industry Network* is being established and we encourage members to [register](#). This new platform will serve as an important communication hub and a key resource for stakeholders across the health genomics community.

Genomics Australia Advisory Council

I am delighted to share my appointment as an independent technical member of the Genomics Australia Advisory Council. I am honoured to be a member of this highly experienced and engaged Advisory Council.

At the first meeting, Ms Tiffany Boughtwood, Australian Health Genomics Commissioner and Chair of the Advisory Council, guided discussion on vision setting for health genomics in Australia. The discussion canvassed priorities and aspirational goals relating to governance, community, services, workforce, data and sustainability, across time horizons of one, five and 10 years. The full meeting communiqué is available via Genomics Australia.

Upcoming Events

InGeNA is progressing summits and roundtables in early 2026.

- **Cell and Gene Summit:** with **ARCS** and DIA on 25 Feb 2026, Sydney - is now open for [registrations](#). InGeNA has partnered on the shaping of the event and I will be chairing a session on how to improve equity and access highlighting the consumer and industry voice. Presenters also include: IDT, HTAnalysts and Laura Issa as a consumer representative.
- **Digital Health Festival** Speaking engagement, 20-21 May, Melbourne
- **Queensland Health Genomics Summit**, 21 May, Brisbane

In parallel, we are in discussions about partnered initiatives focused on genomics-led clinical trials, genomic digital health, AI and genomics. If you are interested in collaborating, please reach out to the InGeNA team.

Performance and Growth

Our Annual Report is now publicly available on our website. We were pleased to

report InGeNA's growth across membership (+113%) and revenue (+75%). In 2026, we look forward to continued growth as new Board Members, Consumer Advisory Group members, and our newly established working groups collaborate to progress our shared goals.

Welcome to Our New Members

A warm welcome to our newest **InGeNA Members, Associate Members and Partners**. Your voices make us stronger as we continue to advance genomics and precision medicine for the health of all Australians.

We look forward to working with you throughout 2026.

Warm regards,

Dr Erin Evans

CEO, InGeNA

InGeNA Members and Partners News

Member Collaboration

The 49th HGSA Annual Scientific Meeting on 1- 4 August 2026 at Te Pae, Christchurch New Zealand.

Our shared booth option for small member organisations is again on offer for 2026. With two confirmed places already, contact [Laena](#) if you would like the costings guide.

Early Bird Registration opens – Feb 2026.



Job Opening

[Genomical Senior Software Engineer](#)



Our members **Gene S** have published a new article, 'Real-World Applications of Pharmacogenomics in Paediatrics', in the **Journal of Paediatrics and Child Health**.

To read the full article and explore how PGx is shaping the future of paediatric medicine, please [visit](#).



23Strands: A New Chapter in Precision Medicine: Introducing Geneve Health PL

Redefining Women's Care Through Precision Medicine - 23Sstrands are proud to announce the commercial launch of Geneve, a comprehensive women's and reproductive health program built on cutting-edge precision medicine, built on three foundational principles. [Read more](#)

InGeNA Welcomes New Members and Partners



InGeNA welcomes associate member

[**Smartways Logistics**](#).

Smartways Logistics is a leading healthcare-focused logistics provider operating across Australia and New Zealand. With a large 24/7 network of drivers and delivery hubs, Smartways specialises in time-critical transport for medical devices, pharmaceuticals, and clinical trial materials. Their services include Patient-on-Table deliveries, cold-chain management, direct drives, and high-touch hospital logistics. Supported by advanced technology for real-



InGeNA welcome's our new Member VCGS ([**Victorian Clinical Genetics Services**](#)).

VCGS are Australian experts in genetic testing, supporting children, adults and families who are living with a genetic condition, or who want to understand their chance of developing one.

They provide:

- clinical care (looking after patients and supporting their doctors)
- genetic screening (tests to identify high or low chance of condition)

time tracking, automation, and data visibility, Smartways delivers reliable, compliant, and transparent service.

The company is also certified carbon-neutral, reflecting a strong commitment to sustainability. Smartways' singular focus on healthcare makes it a trusted partner for hospitals, manufacturers, and life-science organisations.



InGeNA welcomes our newest associate member. [Hartwig Medical Foundation.](#)

Hartwig Medical Foundation Australia is a data and software driven not-for-profit organisation.

Their mission is to build and improve software for molecular diagnostics and treatment/trial matching for today's patient and support a learning healthcare system for future patients through database functionality (storage, reuse, access, connectivity, visualisation).

-and diagnostic testing (test to confirm a condition)

Services span the whole spectrum of life, from before conception through to adulthood.

VCGS is part of Murdoch Children's Research Institute, located at The Royal Children's Hospital Melbourne. They are a not for profit and use proceeds from testing to support medical research and clinical service development.



InGeNA welcomes our Partner - the Genetic Support Network Victoria ([GSNV](#)).

The GSNV are state-wide and serve all people with genetic, undiagnosed and rare conditions, and those who support them. Their work is underpinned by clarity of strategic direction, values and principles and is developed with a focus on Education, Advocacy and Support.

In Australia, it is estimated that 60% of the population will be affected by a condition which has some genetic contribution.

Industry News

09 October 2025, Nature: Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study in Australia

25 November 2025, Innovation Aus: Australia's biotech success is hiding in plain sight

28 November 2025, Catapult: New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy

6 January 2026, Nature: Going beyond genomics in precision oncology

8 January 2026, PRNewswire: Illumina Appoints Dr. Eric Green as Chief Medical Officer

12 January 2026, Inside Precision Medicine: Immune-Related Genes that Shape Pancreatic Cancer Risk and Outcomes Identified

14 January 2026, MJA: Genomic Newborn Screening: Commodity or Public Good?

Upcoming Events

Cell & Gene Summit 25 Feb 2026

An Australia–global dialogue on delivery of advanced therapies. [Registrations](#) now open. Program now available.

Measuring Impact in Healthcare Thursday, March 5, 2026 (9am-4.30pm) @ Rydges, Sydney Central

SIMNA and HTANALYSTS interactive one-day course is designed for busy healthcare professionals.

This workshop provides practical tools to measure impact and build sustainable frameworks for long-term success. [Register](#)

APOS 26 6-7 March 2026, UNSW

Mainstreaming Precision Oncology: Transforming Care Through Science, Medicine and Equity. [Register](#)

RCA Kosi Challenge 13-14 March 2026. The annual iconic fundraising event for RCA. [Registrations](#) are open now

International events

Pre-Approval Access to Medicines in Asia-Pacific (APAC) Conference 2026

March 10, 2026 – March 11, 2026 @
PARKROYAL - 7500 Beach Road

Singapore, 199591 [REGISTER NOW](#)

[Precision medicine world conference](#) Silicon Valley, March 4-6

[Gene Therapy Forum](#)

Boston March, 23-25

PROMO CODE - GT30 - 30% discount

The 49th [HGSA Annual Scientific Meeting](#) on 1-4 August 2026 at Te Pae,
Christchurch New Zealand.

Early Bird Registration opens – February 2026

[Join InGeNA NOW!](#)

New Membership options and partnering opportunities

Find out more with our Membership Brochures and online

Application forms [here](#)



InGeNA Limited, 45 Brisbane Road, Suite 407 Level 4,
Mooloolaba, Queensland, 4557, Australia,

[Unsubscribe](#)

[Manage preferences](#)

Send free email today

HubSpot